Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Respiratory Medicine|July 12, 2005
Microsatellite DNA instability in benign lung diseasesKaterina Samara, Maria Zervou, Nikolaos M Siafakas, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|June 3, 2010
The public's and doctors' perceived role in participation in setting health care priorities in GreeceMamas Theodorou, Katerina Samara, Andreas Pavlakis, et al.
Pulmonary Therapy|July 29, 2024
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND TrialTejaswini Kulkarni, Chad A Newton, Sachin Gupta, et al.
BMJ Open Respiratory Research|October 10, 2025
Use of supplemental oxygen therapy in idiopathic pulmonary fibrosis: an observational real-life study in 16 003 patientsClaire Marant-Micallef, Manon Belhassen, Jean-Michel Fourrier, et al.
Respiratory Medicine|January 18, 2011
New horizons in early stage COPD--improving knowledge, detection and treatmentMarc Decramer, Marc Miravitlles, David Price, et al.
Chest|November 26, 2011
Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseasesEleni G Tzortzaki, Katerina Dimakou, Eirini Neofytou, et al.
ERJ Open Research|July 30, 2024
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosisMichael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, et al.
Advances in Therapy|June 30, 2023
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical StudiesJürgen Behr, Steven D Nathan, Ulrich Costabel, et al.
Pulmonary Pharmacology & Therapeutics|December 14, 2011
Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experienceEleni G Tzortzaki, Andreas Georgiou, Dimitrios Kampas, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Pageof 2